Interview: the antisense evangelist
06 September, 2002 by Melissa TrudingerPersistence has paid off for Stanley Crooke and his company Isis Pharmaceuticals.
AusBiotech recruiting for French devices and diagnostics tour
05 September, 2002 by Iain ScottUp to 20 AusBiotech members are being offered the chance to take part in a medical devices and diagnostics mission in France this November 4-8, under the auspices of the French-Australian Industrial Research (FAIR) program.
Chemeq picks up the pace in South Africa
05 September, 2002 by Melissa TrudingerPerth-based company Chemeq has started its push to introduce its polymeric antimicrobial drug for prevention of colibacillosis in pigs into South Africa, the first country to approve the veterinary product.
MSAC decision disappoints Sirtex CEO
04 September, 2002 by David BinningThe chief executive of Sydney-based company Sirtex has expressed disappointment with the Medical Services Advisory Committee (MSAC) following its surprise rejection of a subsidy application for the company's liver cancer treatment.
Virax to extend trials for HIV/AIDS therapy
03 September, 2002 by Melissa TrudingerMelbourne-based immune therapies company Virax Holdings has announced an extension to its Phase I/IIA clinical trial to further assess the potential of its HIV/AIDS therapy.
GroPep names new CEO
02 September, 2002 by Iain ScottAdelaide-based biotech GroPep has named former Faulding Pharmaceuticals top brass Robert Finder as its new CEO.
Auspep aiming to ride the big waves
29 August, 2002 by Pete YoungAustralian peptide maker Auspep is looking for funds to finance its growth on the back of a market that is jagging upward.
Novogen subsidiary to team with Yale in cancer drug trial
29 August, 2002 by Melissa TrudingerMarshall Edwards Inc (MIE), a subsidiary of Australian pharma Novogen, has announced an agreement with Yale University's Department of Obstetrics and Gynaecology that will allow the Yale researchers to take the company's anti-cancer drug phenoxodiol into clinical trials for ovarian cancer.
GroPep sales up, tips new CEO next week
28 August, 2002 by Iain ScottAdelaide biotech GroPep has blamed the Sydney operations it took over when it acquired Biotech Australia earlier this year for most of the $6.89m loss it sustained in the 2001-02 financial year.
NHMRC kicks off new development funding scheme
28 August, 2002 by Melissa TrudingerThe National Health and Medical Research Council has awarded more than $5 million to 15 researchers seeking to commercialise their discoveries, in the first round of its new development grant scheme.
CK Life mulling state sweeteners
28 August, 2002 by David BinningHong Kong's Cheong Kong Holdings-backed biotech venture CK Life Sciences is yet to decide which state will house its Australian operations, the company said on Tuesday, as it weighs up offers from some very determined suitors.
Metabolic gets good results on obesity drug
27 August, 2002 by Melissa TrudingerMetabolic Pharmaceuticals has achieved another milestone in its development of a weight-loss drug after demonstrating that its obesity drug AOD 9604 is active after oral administration to human patients.
Investment feature: the world's a stage
27 August, 2002 by Pete YoungDrugs, vaccines, diagnostics and devices are the hotspots of the global biomedical market that Australia's biotech researchers are scrambling to fill with products.
ResMed launches lawsuit against competitor
27 August, 2002 by Pete YoungSleep care company ResMed is living up to a reputation for aggressively defending its market position by launching a US patent infringement lawsuit against competitor Fisher and Paykel Healthcare.
Griffith has high hopes for patient monitor
26 August, 2002 by Claire DobleResearchers at Griffith University have developed a new method that monitors patients' vital signs, and sends a message to doctors if there is a problem.
